Archive · 6 Jan 2026
Concord Biotech: Antique Maintains Buy Despite 38% Stock Decline
Concord Biotech is a company that makes medicines.
A family called Jhunjhunwala owns a big part of it.
The company's stock has gone down by 38% in the last year.
But a company called Antique Stock Broking still thinks it's a good investment.
They say the company is well-positioned and has good growth plans.
The company makes different kinds of medicines and has a big factory.
They expect to make more money in the next few years.
Even though there are some problems right now, they think the company will do well in the long run.
Concord Biotech's stock has declined 38% in the past year, but Antique Stock Broking maintains a 'Buy' rating.
The Jhunjhunwala family holds a 24.09% stake in Concord Biotech, valued at Rs 3,374 crore.
Antique expects Concord Biotech to deliver revenue, Ebitda, and PAT CAGR of 18%, 17%, and 19% respectively over FY25 to FY28.
Near-term headwinds include temporary slowdown in CDMO segment due to US market uncertainty and trade-related issues.
Concord Biotech's API business is the primary profit engine, with strong margins due to limited global competition.
- Who
- Concord Biotech Ltd, Antique Stock Broking, Jhunjhunwala family
- What
- Antique maintains 'Buy' rating on Concord Biotech despite stock decline and near-term headwinds
- When
- Near-term challenges expected to persist; long-term growth prospects highlighted
- Where
- Concord Biotech's operations and market positioning
- Why
- Strong fundamentals, integrated business model, and growth levers
- Stake Value
- Rs 3,374 crore
- Stock Decline
- 38% in 12 months
- Revenue CAGR
- 18% (FY25-FY28)
- Ebitda CAGR
- 17% (FY25-FY28)
- PAT CAGR
- 19% (FY25-FY28)
- Target Price
- Rs 1,520
- API to Formulations Mix
- 80:20
- Unit 3 Capacity
- 800-1,200 cubic metres